Implantation of a new porous gelatin-siloxane hybrid into a brain lesion as a potential scaffold for tissue regeneration.
For brain tissue regeneration, any scaffold for migrated or transplanted stem cells with supportive angiogenesis is important once necrotic brain tissue has formed a cavity after injury such as cerebral ischemia. In this study, a new porous gelatin-siloxane hybrid derived from the integration of gelatin and 3-(glycidoxypropyl) trimethoxysilane was implanted as a three-dimensional scaffold into a defect of the cerebral cortex. The porous hybrid implanted into the lesion remained at the same site for 60 days, kept integrity of the brain shape, and attached well to the surrounding brain tissues. Marginal cavities of the scaffolds were occupied by newly formed tissue in the brain, where newly produced vascular endothelial, astroglial, and microglial cells were found with bromodeoxyuridine double positivity, and the numbers of those cells were dose-dependently increased with the addition of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). Extension of dendrites was also found from the surrounding cerebral cortex to the newly formed tissue, especially with the addition of bFGF and EGF. The present study showed that a new porous gelatin-siloxane hybrid had biocompatibility after implantation into a lesion of the central nervous system, and thus provided a potential scaffold for cell migration, angiogenesis and dendrite elongation with dose-dependent effects of additive bFGF and EGF.
Deguchi
Kentaro
K
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmacy, Faculty of Engineering, Okayama University, Okayama, Japan. degu@cc.okayama-u.ac.jp
Tsuru
Kanji
K
Hayashi
Takeshi
T
Takaishi
Mikiro
M
Nagahara
Mitsuyuki
M
Nagotani
Shoko
S
Sehara
Yoshihide
Y
Jin
Guang
G
Zhang
HanZhe
H
Hayakawa
Satoshi
S
Shoji
Mikio
M
Miyazaki
Masahiro
M
Osaka
Akiyoshi
A
Huh
Nam-Ho
NH
Abe
Koji
K
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D001973:Bromodeoxyuridine; D002465:Cell Movement / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005780:Gelatin / Q000008:administration & dosage*; D007150:Immunohistochemistry; D020007:Implants, Experimental; D008297:Male; D010641:Phenotype; D016062:Porosity; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects / Q000502:physiology*; D044968:Regenerative Medicine / Q000379:methods*; D012833:Siloxanes / Q000008:administration & dosage*; D023822:Tissue Engineering / Q000379:methods*
D012833:Siloxanes; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D005780:Gelatin; D001973:Bromodeoxyuridine